ANI Pharmaceuticals reported positive six-month topline results from its Phase 4 SYNCHRONICITY trial evaluating ILUVIEN (fluocinolone acetonide intravitreal implant 0.18 mg) in patients with chronic non-infectious uveitis affecting the posterior segment. The update is supportive of ongoing clinical value for ILUVIEN, though specific efficacy/safety figures and next regulatory/commercial milestones were not provided.
ANI Pharmaceuticals reported positive six-month topline results from its Phase 4 SYNCHRONICITY trial evaluating ILUVIEN (fluocinolone acetonide intravitreal implant 0.18 mg) in patients with chronic non-infectious uveitis affecting the posterior segment. The update is supportive of ongoing clinical value for ILUVIEN, though specific efficacy/safety figures and next regulatory/commercial milestones were not provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
